The present work was a randomized comparative study of two injectable progestogen-only contraceptives. The first group (200 subjects) received 150 mg of depotmedroxyprogesterone acetate (Depoprovera) every 84 +/- 7 days and the second (200 subjects) received 200 mg of norethisterone enanthate (Noristerat) every 56 +/- 7 days. Acceptors of injectable contraceptives in Assiut, Egypt, were mainly women looking for fertility termination. Menstrual disruption was the main side effect among both treatment groups. Amenorrhoea was the commonest menstrual complaint and was the main reason for discontinuation in both groups. Only one pregnancy occurred during NET-EN use; two more pregnancies occurred, one in each of the two groups but there were indications that conception preceded the first injection. Menstrual irregularities were generally more frequent with DMPA users. However, DMPA had better one-year continuation rates than NET-EN (68.8 +/- 3.5 and 57.1 +/- 3.6 per 100 women, respectively).

The present work was a randomized comparative study of two injectable progestogen-only contraceptives. The first group (200 subjects) received 150 mg of depotmedroxyprogesterone acetate (Depoprovera) every 84 +/- 7 days and the second (200 subjects) received 200 mg of norethisterone enanthate (Noristerat) every 56 +/- 7 days. Acceptors of injectable contraceptives in Assiut, Egypt, were mainly women looking for fertility termination. Menstrual disruption was the main side effect among both treatment groups. Amenorrhoea was the commonest menstrual complaint and was the main reason for discontinuation in both groups. Only one pregnancy occurred during NET-EN use; two more pregnancies occurred, one in each of the two groups but there were indications that conception preceded the first injection. Menstrual irregularities were generally more frequent with DMPA users. However, DMPA had better one-year continuation rates than NET-EN (68.8 +/- 3.5 and 57.1 +/- 3.6 per 100 women, respectively).

The present work was a randomized comparative study of two injectable progestogen-only contraceptives. The first group (200 subjects) received 150 mg of depotmedroxyprogesterone acetate (Depoprovera) every 84 +/- 7 days and the second (200 subjects) received 200 mg of norethisterone enanthate (Noristerat) every 56 +/- 7 days. Acceptors of injectable contraceptives in Assiut, Egypt, were mainly women looking for fertility termination. Menstrual disruption was the main side effect among both treatment groups. Amenorrhoea was the commonest menstrual complaint and was the main reason for discontinuation in both groups. Only one pregnancy occurred during NET-EN use; two more pregnancies occurred, one in each of the two groups but there were indications that conception preceded the first injection. Menstrual irregularities were generally more frequent with DMPA users. However, DMPA had better one-year continuation rates than NET-EN (68.8 +/- 3.5 and 57.1 +/- 3.6 per 100 women, respectively).

This report describes the two-year experience of 250 acceptors of NORPLANT implants and 100 TCu-380-Ag IUD acceptors in Assiut, Egypt. The two-year net continuation rate was 67.9 per 100 for implant users and 52.3 per 100 for IUD users. The most important cause for NORPLANT removal was the disruption of menstrual rhythm. However, by the end of the second year, three-quarters of NORPLANT users had monthly menstrual periods and about 60 percent described the amount of blood loss as average, 15 percent as decreased, 15 percent as increased and 10 percent as variable. About 88 percent of the NORPLANT acceptors rated their experience with the contraceptive as good or excellent.

This report describes the two-year experience of 250 acceptors of NORPLANT implants and 100 TCu-380-Ag IUD acceptors in Assiut, Egypt. The two-year net continuation rate was 67.9 per 100 for implant users and 52.3 per 100 for IUD users. The most important cause for NORPLANT removal was the disruption of menstrual rhythm. However, by the end of the second year, three-quarters of NORPLANT users had monthly menstrual periods and about 60 percent described the amount of blood loss as average, 15 percent as decreased, 15 percent as increased and 10 percent as variable. About 88 percent of the NORPLANT acceptors rated their experience with the contraceptive as good or excellent.

This report describes the five-year experience of the first 250 acceptors of NORPLANT implants in Assiut, Egypt. The five-year net continuation rate was 58.6 per 100 women. The five-year net cumulative pregnancy rate was 1.6 per 100 women. About three-fourths of those who continued use of this contraceptive through the fifth year reported having regular cycles. There was definite improvement in the bleeding pattern with time. The five-year net termination rate because of bleeding problems was 17.7 per 100 women. After 5 years of NORPLANT use there was a slight, statistically insignificant increase in weight, systolic and diastolic blood pressures. Of those who used contraceptives after the end of the five-year term of NORPLANT, about one-third opted to have reinsertion of the implants for a second term. About 96% of those who used NORPLANT through the fifth year reported that their experience with the contraceptive had been satisfactory.

This report describes the five-year experience of the first 250 acceptors of NORPLANT implants in Assiut, Egypt. The five-year net continuation rate was 58.6 per 100 women. The five-year net cumulative pregnancy rate was 1.6 per 100 women. About three-fourths of those who continued use of this contraceptive through the fifth year reported having regular cycles. There was definite improvement in the bleeding pattern with time. The five-year net termination rate because of bleeding problems was 17.7 per 100 women. After 5 years of NORPLANT use there was a slight, statistically insignificant increase in weight, systolic and diastolic blood pressures. Of those who used contraceptives after the end of the five-year term of NORPLANT, about one-third opted to have reinsertion of the implants for a second term. About 96% of those who used NORPLANT through the fifth year reported that their experience with the contraceptive had been satisfactory.

Introduction: Turner syndrome is a genetic disorder that affects only females and is caused by the loss of the whole or a part of the X-chromosome. The aim of this study was to assess the quality of life and frequency of anxiety and depression in a cohort of Egyptian children with Turner syndrome (TS) diagnosed in Assiut university hospitals, Assiut, Egypt. Methods: In a case-control study; 40 females with Turner Syndrome (TS), aged 6-16 years, diagnosed in Assiut university hospitals, Upper Egypt, were compared to 40 age- matched apparent healthy girls as controls. They were subjected to full history taking, thorough clinical examination and assessment of pediatric quality of life; we used pediatric anxiety and depression scores. For cognitive assessment, health-related quality of life (HR-QOL) and psychological evaluation of anxiety and depression; we used the "Children Depression Scale" (CDI), "Children Anxiety Scale" Wechsler Intelligence Scale for children (WISC), and SF-36 by trained psychiatrists blind to the study. Results: Our study revealed Children Anxiety Scale scores ranged from 13-41 for patients with TS and 5-23 for controls. The mean anxiety scores were significantly higher in TS patients as compared to controls (p 0.001), (27.32 ± 7.1 versus 15.2± 2.9). In addition, we found CDI scores ranged from 38-70 for patients and 31-56 for controls. Mean depression scores were significantly higher in TS patients as compared to controls (p 0.001), (54.7 ± 8.8 versus 36.8 ± 9.9). The physical and mental component summary scores of HR-QOL were lower in TS patients when compared to controls. Conclusion: We concluded that female children with TS experience significant problems with HR-QOL, anxiety and depression, which need thorough psychiatric evaluation and rapid intervention of these patients.